These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 15562745)
1. Effect of gender on reporting of MMR adverse events in Saudi Arabia. Khalil MK; Al-Mazrou YY; Al-Ghamdi YS; Tumsah S; Al-Jeffri M; Meshkhas A East Mediterr Health J; 2003; 9(1-2):152-8. PubMed ID: 15562745 [TBL] [Abstract][Full Text] [Related]
2. Adverse events following immunisation associated with the 1998 Australian Measles Control Campaign. D'Souza RM; Campbell-Lloyd S; Isaacs D; Gold M; Burgess M; Turnbull F; O'Brien E Commun Dis Intell; 2000 Feb; 24(2):27-33. PubMed ID: 10758692 [TBL] [Abstract][Full Text] [Related]
3. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. Miller E; Andrews N; Stowe J; Grant A; Waight P; Taylor B Am J Epidemiol; 2007 Mar; 165(6):704-9. PubMed ID: 17204517 [TBL] [Abstract][Full Text] [Related]
4. Safety evaluation of MMR vaccine during a primary school campaign in Saudi Arabia. Al-Mazrou Y; Tumsah S; Khalil M; Al-Jeffri M; Afzal MA; al-Ghamdy Y; Mishkhas A; Essa M J Trop Pediatr; 2002 Dec; 48(6):354-8. PubMed ID: 12521278 [TBL] [Abstract][Full Text] [Related]
5. Surveillance of measles-mumps-rubella vaccine-associated aseptic meningitis in Germany. Schlipköter U; Mühlberger N; von Kries R; Weil J Infection; 2002 Dec; 30(6):351-5. PubMed ID: 12478324 [TBL] [Abstract][Full Text] [Related]
6. No demonstrable association between the Leningrad-Zagreb mumps vaccine strain and aseptic meningitis in a large clinical trial in Egypt. Sharma HJ; Oun SA; Bakr SS; Kapre SV; Jadhav SS; Dhere RM; Bhardwaj S Clin Microbiol Infect; 2010 Apr; 16(4):347-52. PubMed ID: 20222892 [TBL] [Abstract][Full Text] [Related]
7. Aseptic meningitis: case definition and guidelines for collection, analysis and presentation of immunization safety data. Tapiainen T; Prevots R; Izurieta HS; Abramson J; Bilynsky R; Bonhoeffer J; Bonnet MC; Center K; Galama J; Gillard P; Griot M; Hartmann K; Heininger U; Hudson M; Koller A; Khetsuriani N; Khuri-Bulos N; Marcy SM; Matulionyte R; Schöndorf I; Sejvar J; Steele R; Vaccine; 2007 Aug; 25(31):5793-802. PubMed ID: 17574313 [No Abstract] [Full Text] [Related]
8. Adverse reactions following immunization with MMR vaccine in children at selected provinces of Iran. Esteghamati A; Keshtkar A; Heshmat R; Gouya MM; Salar Amoli M; Armin S; Mahoney F Arch Iran Med; 2011 Mar; 14(2):91-5. PubMed ID: 21361714 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine. LeBaron CW; Bi D; Sullivan BJ; Beck C; Gargiullo P Pediatrics; 2006 Oct; 118(4):1422-30. PubMed ID: 17015532 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835 [TBL] [Abstract][Full Text] [Related]
11. A serological survey of measles, mumps and rubella immunity among school aged children in Western Saudi Arabia. Jaber SM Saudi Med J; 2006 Jan; 27(1):63-9. PubMed ID: 16432596 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Vesikari T; Baer M; Willems P Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879 [TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age. Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. Goh P; Lim FS; Han HH; Willems P Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370 [TBL] [Abstract][Full Text] [Related]
15. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003. Asatryan A; Pool V; Chen RT; Kohl KS; Davis RL; Iskander JK; Vaccine; 2008 Feb; 26(9):1166-72. PubMed ID: 18255204 [TBL] [Abstract][Full Text] [Related]
17. Measles immunization in Saudi Arabia: the need for change. Khalil MK; Al-Mazrou YY; Al-Jeffri M; Al-Ghamdy YS East Mediterr Health J; 2001; 7(4-5):829-34. PubMed ID: 15332786 [TBL] [Abstract][Full Text] [Related]
18. Simultaneous vaccination of Chinese applicants for a United States immigrant visa. Hua L; Hongtao H; Shunqin W; Jinping G; Jiandong C; Zhaoliang L; Xinwen F Travel Med Infect Dis; 2008 May; 6(3):130-6. PubMed ID: 18486068 [TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM; Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199 [TBL] [Abstract][Full Text] [Related]
20. Statistical analysis of MMR vaccine adverse events on aseptic meningitis using the case cross-over design. Park T; Ki M; Yi SG Stat Med; 2004 Jun; 23(12):1871-83. PubMed ID: 15195321 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]